Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 132965Generated: October 30, 2026

4-Methylmorpholine → (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-hydroxypyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide

https://huagongshe.com/reaction/132965

Reaction equation

Participants

RoleNameHCIDCharge
Reactant4-MethylmorpholineHCID 7972—
ReactantMethanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 9886157—
Reactant(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-4-phenylbutanoic acidHCID 67270863—
Reactant(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((R)-1-benzhydrylpiperidin-2-yl)-3-(3,5-difluorophenyl)-1-hydroxypropan-2-yl)-4-phenylbutanamideHCID 69194179—
Reactant(1S,2S)-2-amino-1-((2R,4S)-1-benzhydryl-4-(pyridin-2-yloxy)pyrrolidin-2-yl)-3-(3,5-difluorophenyl)propan-1-olHCID 69195403—
Reactant(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((2R,4R)-1-benzhydryl-4-hydroxypyrrolidin-2-yl)-3-(3,5-difluorophenyl)-1-hydroxypropan-2-yl)-4-phenylbutanamideHCID 69196374—
SolventDimethylformamideHCID 6228—
Product(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-hydroxypyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamideHCID 6919651565%

Reaction Steps

Step 14 (B): (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((2R,4R)-1-benzhydryl-4-hydroxypyrrolidin-2-yl)-3-(3,5-difluorophenyl)-1-hydroxypropan-2-yl)-4-phenylbutanamide. To a solution of (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-4-phenylbutanoic acid (Preparation A, 22.6 mg, 0.063 mmol) in DMF (1 mL) was added HATU (28.7 mg, 0.076 mmol). A solution of (3R,5R)-5-((1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl)-1-benzhydrylpyrrolidin-3-ol (Step 14 (A), 27.5 mg, 0.063 mmol) in DMF (1 mL) was then added, followed by N-methylmorpholine (24.2 μl, 0.221 mmol). The reaction mixture was stirred at rt for 3 h. pH 4 buffer was then added to quench. The mixture was extracted with ethyl acetate. The organic phase was washed with sat. aqueous NaCl, dried (MgSO4), and concentrated in vacuo. The crude mixture was purified by reverse phase Prep HPLC to give the title compound (32 mg, 65% yield) as a slightly yellow oil: 1H NMR (CDCl3, 500 MHz) δ 0.88 (3H, d, J=10 Hz), 1.00 (3H, m), 1.07-1.18 (1H, m), 1.55-1.61 (1H, m), 1.72-1.78 (1H, m), 1.95-2.03 (4H, m), 2.05-2.11 (2H, m), 2.30 (2H, d, J=15 Hz), 2.38-2.47 (1H, m), 2.48-2.53 (1H, m), 2.64-2.70 (1H, m), 2.88 (1H, m), 3.03-3.08 (3H, m), 3.17-3.20 (1H, m), 3.49 (1H, s), 3.53-3.61 (3H, m), 3.91 (1H, d, J=10 Hz), 3.96 (3H, s), 4.11 (1H, m), 4.47 (1H, brd s), 4.96 (1H, brd s), 6.13 (1H, brd s), 6.58-6.67 (3H, m), 7.04-7.37 (10H, m), 7.49 (2H, m), 7.67 (2H, d, J=10 Hz). HPLC retention time: 1.67 min (method A). MS (ESI) (M+H)+ 781.35.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07388007B2
Source datasetuspto-grants-2008_06
ORD IDord-ae4f59e65419479dbad1a7a4543563c8
Source noteuspto-grants-2008_06